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Abtsract 
A four step process of high quality modelling of existing data, deconstruction, identification of 
replacement cores and an innovative synthetic re-growth strategy led to the rapid discovery of a novel 
oral series of PI3KG inhibitors with promising selectivity and excellent in vivo characteristics. 
Introduction 
The phosphoinositide-3-kinases (PI3Ks) are a family of lipid kinases that are implicated in the 
development of a range of diseases, including respiratory inflammation.1,2  They comprise three 
classes based on structure, mode of regulation and phospholipid substrate.  The class I targets have 
been extensively investigated due to their role in various cancers and inflammatory disease,3 with 
their biochemical role mediating the phosphorylation of  phosphatidylinositol (4,5)-diphosphate 
(PtdIns(4,5)P2), to produce phosphatidylinositol (3,4,5)-triphosphate (PtdIns(3,4,5)P3).4 A number of 
studies have highlighted the correlation between PI3K-mediated PIP3 production and T cell cytokine 
release5, mast cell degranulation,6 neutrophil chemotaxis,7 and the production of reactive oxygen 
species.8  These cell behaviours have been implicated in the development of respiratory inflammation 
and a range of cancers. Of the known isoforms, PI3KG is found to be predominantly expressed in 
leucocytes suggesting it is a promising target for the treatment of asthma,9 COPD,10 and autoimmune 
disorders.11 From a drug discovery perspective, selectivity among the isoforms is an important 
consideration; both PI3KG and J knock-out mice are viable and display some impairments of immune 
cell functions,12,13 however, PI3KD DQGȕNQRFN-outs have been shown to be embryonically lethal.12 
We recently reported the discovery of an inhaled clinical candidate GSK2292767 (1, Figure 1) as a 
potent and selective PI3KG inhibitor with promising in vivo properties as a potential therapy for 
respiratory indications14. This compound is structurally related to GSK2269557, also an inhaled 
therapy and currently in Phase II trials for COPD and asthma. Orally bioavailable compounds such as 
IPI-14515 and GS-1101 (CAL-101, Idelalisib)16 have previously been reported and advanced through 
clinical studies for oncology indications. Compounds of a similar structural genus have also appeared 
more recently, for example UCB-5857 and TGR-1202. All derive from the same chemical series 
which generally possesses mixed PI3KG/J inhibition and this lack of selectivity creates difficulties in 
delineating the role of either isoform in inflammatory disease. More recently still researchers from 
Amgen reported potent, selective and orally bioavailable PI3KG inhibitors for the treatment of 
inflammatory disorders (e.g. AM-8508, 2)17 and Novatis have progressed CDZ-173 into phase III 
trials for the treatment of activated PI3K delta syndrome. Taken together these events highlight the 
significant and continuing level of interest associated with this promising therapeutic target.  In the 
current study, we disclose our early efforts towards the discovery of a series of PI3KG selective, orally 
bioavailable compounds exemplified by the dihydroisobenzofuran derivative 3 (Figure 1) derived 
from our existing inhaled asset 1 as a potential therapy for respiratory disorders. The aim of the study 
was to discover an alternative core with reduced clearance and increased bioavailability whilst 
retaining the potential to deliver the class-leading levels selectivity demonstrated by compounds such 
as 1. 
 Figure 1. Structures of 1, 2 and 3. 
Results and Discussion 
Our progenitor compound 1 was developed for delivery by the inhaled route and exhibited negligible 
oral bioavailability (< 2%) with very low exposure (Cmax <2ng/mL, 3mg/kg p.o.) and only a small 
sub-set of the compounds prepared in this series possessed moderate bioavailability and clearance. 
With this in mind, we elected to pursue a four stage approach in order to evolve a series more suited 
to oral adsorption. 1) Utilise all available information to guide future approaches. 2) Deconstruct the 
current series to identify key features and provide an efficiency baseline. 3) Replace or remove 
perceived vulnerable moieties in the deconstructed molecules to provide a wide range of future 
options. 4) Select options with distinct risk profiles for re-growth/optimisation. 
Step 1 ± Utilisation of legacy information. Replacement of the indazole core was motivated in part by 
a desire to reduce the aromatic ring count18 but primarily by contemporaneous literature reports that 
implicated the indazole group19 as a target for time-dependent P450 inhibition. The general design 
strategy involved tuning of TPSA20 (<135 Å2) and limitation of molecular weight through 
consideration of ligand efficiency.21 To further refine our approach two proprietary data-sets were 
inspected with a view to minimise oral dose. These were factors affecting clearance (in vitro and in 
vivo) and cellular potency/drop off. Whilst the clearance data presented no potentially transferable 
trends the data from the cell assays provided significantly more insight. The difference between the 
primary assay and cellular whole blood (bio phase) assay was calculated and this difference was 
modelled using a multivariate data analysis technique called Partial Least Squares regression,22 
involving a standard set of physicochemical descriptors. The model was used to identify and explore 
potential relationships between molecular properties and the measured difference. The Loadings Plot 
(Figure 2) explores the relationship between variables themselves and also between response in 
question. An examination of the plot highlighted three clusters of variables which led to assessment of 
which parameters were important. The associated Coefficient Plot summarises the magnitude and 
direction of influence of each variable. 
Three key trends emerged from the data: i) Variables 5-9 are calculations of lipophilicity and 
appeared to be associated with a detrimental effect on drop-off between enzyme and whole blood 
potency; ii) Variables 11 and 12 suggested that ionisation, in particular addition of a basic centre, was 
beneficial to minimizing the drop-off between enzyme and biofluid activity; iii) The group of 
variables 23, 24 and 25 related to increased hydrogen bond donor count were detrimental to whole 
cell activity. The impact of lipophilicity and basic centres was attributed primarily to modulation of 
protein binding for which optimisation was not a priority; however, the negative impact of hydrogen 
bond donors, but not acceptors, drew our attention and impacted on our subsequent design strategy 
(vide infra). It is interesting to note that PI3Kdelta potency (variable 2) positively correlates with 
cellular drop off, albeit with very high variability, and it is not unlikely that this observation results 
from a relationship between lipophilicity and potency. 
 
Figure 2 (a) PLS Loadings Plot demonstrating groups of coefficients (b) PLS Coefficient Plot 
indicating magnitude, direction and 95% confidence interval of the mean. Variables of interest: Var 5-
8 (ACD Labs v11.logd at pH2, 5.5, 6.5 & 7.4) and Var 9 (clogP 481); Var 11  (positive ionisable 
centre count) and Var 12 (total charge); Var 23 (estate.amideNH-sum), Var 24 (estate.amideNH-av) 
and Var 25 (estate.amideOtoNH-av). NB Var 2 is PI3K delta potency. 
Step 2 ± Deconstruction. A deconstruction (Dx, Figure 3) of compound 1 was performed to establish 
the minimum necessary pharmacophore and maximal potential efficiency of the lead series. It was 
anticipated that scanning for replacement components at a reduced complexity level would be 
considerably more synthetically tractable. Furthermore, scanning with fully-elaborated compounds 
runs the risk of small changes in optimal binding pose of the core preventing efficient binding of the 
entire molecule. For efficiency measurements we adopted Binding Efficiency Index23 (BEI = 1000 x 
(pIC50/MW)) as our efficiency metric given that in our hands it proved to be intuitive to use yet 
correlates24 very well with the more widely used Ligand Efficiency (LE). The deconstruction was 
conducted with some knowledge of the binding of the molecule14  gleaned from homology modelling 
prior to the later generation of a crystal structure. The indazole core fragment (red) occupies the 
NLQDVHµKLQJH¶UHJLRQWKHS\ULG\OVXOIRQDPLGHEOXHHQWHUHGWKHOLSLG-NLQDVHµEDFN¶SRFNHWZKLOVWWKH
oxazole/morpholino group (magenta) occupied a vector that delivered majority of selectivity for 
PI3KG. 
 
Figure 3. Design strategy for oral series. The calculated potency is derived via  the rearranged BEI 
calculation (cPI3KG pIC50 = 320 x (BEI/1000))  
The parent pyridine sulfonamide back-pocket binder (blue) was chosen as a structural lock. BEI 
calculations suggested that truncate 4 should be significantly above the limit of detection of the assay 
(pIC50 ~ 5) assuming a BEI of 18-20, hence allowing replacement hinge binding groups to be profiled. 
Synthesis and evaluation of 4 (Table 1) confirmed the anticipated level of potency against PI3KG, 
validating its use as a benchmark for replacement groups.  
Step 3 - Identification of replacement hinge-binding groups. A variety of potential hinge-binding 
groups were then scanned and one of the most promising hits from this exercise was the 
dihydroisobenzofuran analogue 5 (Table 1) as a potentially novel replacement. This moiety increased 
solubility which was perhaps surprising given the higher measured LogD of the compound. We 
reasoned that this may be the result of destabilisation of the solid form as a consequence of reduced 
planarity and elimination of inter-molecular hydrogen bonds. This observation, coupled with the 
previous analysis suggesting the benefit of reduced HBD count, encouraged us to re-institute the 
selectivity vector on this template to establish the potential for obtaining selectivity, whole blood 
efficacy and favourable DMPK parameters. 
Table 1. Profile of reduced complexity analogue 4 and indazole replacement 5. 
 
*pKi14 
 
Ar   
 
 4 5 1 
3,.įS,&50 (n, BEI) 6.0 (4, 18.9) 6.1 (6, 19.0) 10.1* (2, 19.7) 
PI3KDEJpIC50 (n) 5.1, 5.1, 5.6 (5) 5.4, 5.7, 5.5 (6) 6.3, 6.2, 6.3 (17+) 
Chrom LogD pH 7.4 2.6 3.5 3.3 
TPSA 97 78 135.5 
Aryl Rings/HBD 3/2 2/1 4/2 
6ROXELOLW\ȝJP/ 31 92 182 
Step 4 ± Re-growth and optimisation. Having established the feasibility of replacing the indazole core, 
the subsequent phase of the optimisation trajectory focused on re-establishing the selectivity vector at 
the 6-position of the dihydroisobenzofuran template. The design hypothesis at this stage focused on 
generating compounds that would facilitate a thorough comparison with the indazole series and lead 
to an understanding of how well the SAR would transfer between the two series.  To select the most 
appropriate functional groups for the 6-position, we considered the structures of PI3KG compounds 
previously synthesised in our laboratories, focusing on the key pyridylsulfonamide motif.  The subset 
of compounds identified from this approach was further filtered through applying physicochemical 
property constraints that would be likely to furnish compounds with oral bioavailability. This analysis 
led to the identification of six potential substituents for inclusion at the 6-position of the 
dihydroisobenzofuran which spanned a variety of different chemotypes and offered a range of PI3K 
class I selectivity profiles.  The substituents of interest are shown in Figure 4 as part of the 
dihydroisobenzofuran motif, with calculated physicochemical parameters shown in Table 2. 
 
Figure 4.  Target 6-position substituents in the dihydroisobenzofuran series. 
The calculated physicochemical data is summarised in Table 2. In addition to reduced hydrogen bond 
donor count, target compounds had lower TPSA than the progenitor inhaled compound 1 and we 
anticipated that this could potentially translate into improved oral exposure.20 Other aspects of the 
physicochemical profile such as number of aromatic rings are lower, leading to potential 
improvements in Property Forecast Index (PFI), again increasing the probability of enhancing oral 
exposure.18 The overall hydrogen bond donor count is included in the table; however, it is worth 
noting that all of the compounds contain one fewer donor than the corresponding progenitor 
indazoles. 
Table 2. Calculated physicochemical properties for compounds 6 to 10. 
Phys. Chem. Property 6 7 8 9 3 10 
MW 402 397 377 461 463 455 
cLog P 1.1 2.9 1.5 2.8 2.9 1.6 
TPSA 116 90 107 120 120 120 
No. Ar rings 3 3 2 3 2 3 
Rotatable bonds 4 4 4 5 6 5 
Hydrodgen Bond Donors 1 1 2 2 2 2 
 
Chemistry 
Reduced complexity analogues 4 and 5 were prepared using a Suzuki-Miyaura coupling from the 
pinacol boronic ester 11, Scheme 1. 
 
Scheme 1 Reagents and conditions (i) Boronate ester 11, 6-bromo-1H-indazole, Pd2(dba)3, 
tBu3P.HBF4, KF, 2-methylTHF/water (3:1), 28%. ii) Boronate ester, 5-bromo-1,3-
dihydroisobenzofuran, PdCl2(dppf).DCM, CsOAc, KF, THF/water (20:1), 39%. 
The fully elaborated dihydroisobenzofuran core was accessed in an efficient manner utilising a 
ruthenium mediated cyclotrimerisation reaction as outlined in Scheme 2. The tethered [2+2+2] 
trimerisation of terminal alkynes preferentially installs the required meta arrangement of R4 and R6. 
Judicious selection of these groups allows excellent flexibility to the medicinal chemist and synthesis 
of a wide variety of targets in short order (4-6 steps). Literature reports25 suggested that trimethylsilyl 
tethered diynes (R6=TMS) exhibit excellent regiochemistry in this reaction and ipso substitution of the 
resulting aryl silane to iodide is well known (vide infra). It is worth noting that the route also provides 
the opportunity to make other changes to the core framework. For example use of nitriles (A=N) 
allows access to pyridyl analogues and elaboration at R2 and R7 readily facilitates substitution 
adjacent to the hinge-binding oxygen atom, therefore the investment was made in enabling this 
potentially challenging chemistry. 
 
Scheme 2 Synthetic plan for the utilisation of 2+2+2 trimerisation chemistry. 
Alkyne 13 was prepared as indicated in Scheme 3 and the TMS-protected bispropargylether 12 
prepared in one step from propargyl ether according to the literature procedure.26  
 
Scheme 3. (i) Pd(PPh3)2Cl (8 mol%), CuI (8 mol%), Et3N (4eq), 2-Me THF, 80 °C, quantitative; (ii) 
KOH, iPrOH, reflux, 77%. 
The synthesis of the target compounds is described in Scheme 4. Optimisation of cyclotrimerisation 
conditions revealed that cyclopropylmethyl ether (CPME) was preferable to the commonly used 
dichoroethane as solvent.27 The key aryl silane intermediate 14 was thus obtained in good yield with 
either a 1.2 eq excess of 12 or a 2.0 eq excess of 13. Ipso substitution of 14 with iodine monochloride 
then provided the iodo derivative 15 in excellent yield. Palladium-mediated cross coupling provided 6 
and 7 using either a Negishi protocol28 or modified Suzuki-Miyaura procedure,29 respectively. Copper 
mediated amination of 15 provided aniline 16 which was then converted to amides  3, 8, 9 and 10.  
 
Scheme 4. (i) RuCp*(cod)Cl (10 mol%), CPME, r.t., 64% (1.2 eq 12 or 2.0eq 13); (ii) ICl, CH2Cl2, 10 
± 0 °C, 80%; (iii) CuI (20 mol %), L-Proline, Cs2CO3, DMSO:NH3 (aq) (1:1), 110 °C, µwave, 77%; 
(iv) 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine, Pd(OAc)2 (1 mol %), Cs2CO3, dppf (20 
mol %), CuCl (100 mol%), DMF, µwave, 100 °C, 10%; (v) (a) 2-methyl-1,3,4-oxadiazole, LiHMDS, 
ZnCl2, THF, -10 °C; (b) Pd(PPh3)4 (10 mol%), Cs2CO3ȝZDYH&YL5&22H, HATU, 
DMF, r.t., 21- 28%. 
The in vitro potencies of the target compounds were measured in a homogenous time-resolved 
fluorescence assay as described previously.14  The results from these assays (Table 4) indicate good 
OHYHOV RI SRWHQF\ DJDLQVW WKH 3,.į LVRIRUP ZLWK S,&50 values ranging from 6.4 to 8.3. The more 
structurally elaborated thiazole 9 and pyridine 10 display the most encouraging potency and 
selectivity profiles, providing support the original hypothesis that functionalisation at the 6-position of 
the dihydroisobenzofuran core would provide an enhancement of activity. In relation to PI3K class I 
selectivity, the majority of the analogues showed an encouraging profile in comparison to the 
progenitor dihydrosiobenzofuran 5, particularly compounds 9, 3 and 10. In general the isoform 
selectivity observed was lower than the fully optimisied inhaled candidate molecule; however, 
comparison to the previously reported thiazole analogue 20 indicates similar selectivity is retained 
with the new hinge binder. Accordingly, we reasoned that selectivity could be improved by further 
optimisation of the 6-position vector. 
Table 4. Isolated enzyme assay results for the PI3K class I isoforms. 
 
Compound Number R 
PI3K Class I isoforms 
pIC50 6HOHFWLYLW\YV3,.į5DWLR 
į Į ȕ Ȗ 
1 ,QKDOHG3,.įOHDG 10.1* 631 794 631 
5 H 6.1 5 2.5 4 
6 
 
7.7 5 13 5 
7 
 
7.2 10 20 6 
8 
 
6.4 4 13 13 
9 
 
8.1 50 63 25 
20 - 7.9 63 63 16 
3 
 
6.8 25 63 50 
10 
 
8.3 50 126 25 
*pKi quoted14 
Based on this promising initial data, and to more fully benchmark this nascent lead series, a selection 
of compounds was made for further profiling in both whole blood14 to assess the cellular activity of 
each compound and DMPK30 assays, as well as other developability screening. The results of these 
studies are summarised in Table 5. 
Table 5. Further profiling of dihydroisobenzofuran analogues. 
 
 
Inhaled 
PI3Kį lead 
 
R 
 
   
Compound number 1 6 3 10 
3,.įLVRODWHGHQ]\PH
(pIC50) 
9.1 7.7 6.8 8.3 
3,.įwhole blood (pIC50) 8.4 6.7 6.6 6.7 
IVC rat, mouse, human liver 
microsomes (mL/min/g) 
1.9, 5.9, 3.2 <0.5, 1.0, <0.5 <0.5, <0.5, <0.5 1.2, 1.4, <0.5 
AUCinf (p.o., ng.h/mL) < 24 1370 673 42* 
 In vivo PK data in Table 5 were obtained in the CD Sprague male rat following administration of 
1mg/kg oral and iv doses. *AUC0-t quoted. 
Comparing the whole blood potencies for the newly synthesised compounds shows a drop off cellular 
activity of at least ten fold or greater for compounds 6 and 10. By contrast, compound 3 exhibits only 
minimal attenuation in cellular potency compared to the isolated enzyme data.  A likely contributor to 
this difference is protein binding given that compound 3 has an estimated free fraction of 36%, 
whereas the other analogues examined have an estimated free fraction of 10% or less. It is worth 
noting that whilst these compounds are substantially weaker than the inhaled lead in whole blood cell 
assays; however, there is a stronger imperative for potency for an inhaled molecule due to the 
necessity of a very low dose. The whole blood activity of 3, 6 and 10 compare favourably with oral 
compounds in clinical development, for example the PI3KGJ inhibitor IPI-145 inhibits basophil 
degranulaton with an IC50 of 96nM (pIC50~7.0) in whole blood15. 
All three compounds display much improved metabolic stability when compared to the inhaled lead 1 
in both in vitro and in vivo studies.  In vitro clearance (IVC) levels in all species investigated are low 
to moderate, whilst rat in vivo clearance for compound 3 of less than 14 mL/min/Kg equates to less 
than 20% liver blood flow (Table 5).  The slightly elevated observed clearance of morpholine 3 with 
respect to oxadiazole 6 and pyridine 10 could be attributed to the lower level of protein binding 
(HSA), which may increase the fraction of drug exposed to organs of metabolism and excretion. The 
relatively low volumes of distribution for compounds 6 and 3 result in lower half-lives compared to 
pyridine analogue 10. It was reasoned that further optimisation of the 6-position (e.g. modulation of 
the basic amine) could increase volume of distribution and positively impact the half-life. 
Half Life, T ½ (i.v.) (hr) 2.6 0.9 1.3 3.4 
Cl (i.v.) (mL/min/Kg) 50.0 6.9 14 6.0 
Oral Bioavailability, F (%) < 2.0 56 54 1.5 
Vdss (L/Kg) 3.5 0.5 1.1 1.6 
HSA binding (%) 90 90 64 93 
CLND Solubility (µg/mL) 182 195 185 50 
MDCK passive perm. (nm/s) 213 803 122 758 
Low bioavailability is observed for pyridine 10 despite its low systemic clearance and excellent in 
vitro passive permeability measured on MDCK cells. First pass metabolism or poor absorption from 
the GI tract are therefore unlikely causes of the low bioavailability and it is more likely that this is 
attributed to the low solubility of pyridine 10 (50 µg/mL) when compared to the other 
dihydroisobenzofuran analogues examined. Oxadiazole 6 and morpholine 3 show significantly higher 
bioavailability than the inhaled lead 1, thus validating the initial design hypothesis in controlling 
physicochemical properties. Furthermore, morpholine 3 is among a paucity of compounds from this 
chemotype which exhibit both oral bioavailability and greater than 20 fold PI3K class I selectivity in 
isolated enzyme assays. In addition to this, compound 3 also exhibited excellent selectivity against a 
varied panel of kinases and other enzymes.31 Based on all of the above, we believe that the 
dihydroisobenzofuran series UHSUHVHQWV D VLJQLILFDQW DGYDQFH LQ WKH GHVLJQ RI VHOHFWLYH 3,.į
compounds which are suitable for oral administration. 
Compound 3 was also successfully co-crystallised with PI3KG which confirmed the proposed binding 
mode with the kinase (Figure 5). From our earlier studies, the indazole was shown to be a hinge 
binding motif14 and this interaction is effectively maintained by the dihydroisobenzofuran, albeit that 
any interaction between the indazole NH and the hinge has been lost.  The 6-position substituent 
forms a similar vector to that observed with the inhaled lead 1; however, the core benzenoid ring 
appears to be rotationally displaced by approximately 15 degrees which suggests that the optimal 6 
position groups could differ between the two series. It is also worth noting that the morpholine 
substituent does not reach the same region of the protein as that occupied by 1 leading to the 
hypothesis that further selectivity can be obtained. Given the rotational displacement of the core it is 
postulated that complete re-optimisation of the linking group is required to allow the morpholine 
group to access the region occupied by 1. 
Figure 5. X-ray structure of compound 3 (cyan) co-crystallised with PI3KG and over-layed with a 
crystal structure of compound 1 (orange). 
  
Based on its promising oral bioavailability and encouraging level of cellular potency the morpholine 
analogue 3 was progressed to an in vivo pharmacodynamic assay to determine its efficacy in a disease 
relevant animal model. In our previous report a Brown Norway rat acute OVA model of lung 
inflammation was used14. Compound 3 was assessed using this model whereby OVA challenge is 
administered 30 minutes after oral delivery. Significant protection against eosinophil recruitment was 
achieved by compound 3 at 3 mg/kg p.o (Figure 6) whereas failure to achieve significance at 9mg/kg 
is primarily attributed to two poorly responding rats in this group.  
The pharmacokinetic data from the study is presented in Table 6 along with the comparative data 
from the pilot pharmacokinetic study. Interestingly 3 achieved lower exposure in the OVA study at 
3mg/kg when compared to the pilot study (1mg/kg) which may be result from strain dependency 
and/or differences in dose formulation. The blood concentration of 3 one hour after dosing, i.e. 30 
minutes after OVA challenge, are 0.19uM and 1.27uM for the 3mg/kg and 9mg/kg groups 
respectively which compare very favourably with the pIC50 in human whole blood (6.6, 0.25uM, vide 
supra). The estimated free drug concentrations at this time-point are also provided. 
From consideration of all the above data, morpholine 3 represents the inception of a promising series 
of 3,.įLQKLELWRUVwith good oral bioavailability and robust levels of in vivo efficacy. This compares 
favourably WRWKHEHQFKPDUNVHWE\WKHRUDOO\ELRDYDLODEOHGXDO3,.ȖįGXDOLQKLELWRU,3,-145, which 
demonstrates similar levels of in vivo efficacy in a related pharmacodynamic study and has recently 
completed a Phase 2a trial for asthma. 
This highly encouraging data provides additional validation for the design strategy adopted in 
developing a new hinge binder, thereby providing confidence in further developing the 
dihydroisobenzofuran series to further optimise its selectivity and DMPK characteristics. 
Figure 6. Pharmacodynamic Testing of compound 3 in an acute model of lung inflammation.  
 
The data in Figure 6 was analysed using an analysis of variance model with the log eosinophil 
numbers as the response with treatment including the controls fitted as a categorical factor. The 
plotted intervals represent the 95% confidence interval of the mean response. 
Table 6. Compiled pharmacokinetic data on compound 3 from pilot rat PK and PKPD studies 
Dose 
(mg/kg) 
Strain AUCinf 
(hr.ng/ml) 
T1/2 
(hr) 
Blood conc. 1hr 
(ng/ml (uM)) 
Unbound conc*. 1hr 
(uM) 
1 WH 673 - 240 (0.52) 0.089 
3 BN 454 10.6 86.9 (0.19) 0.032 
9 BN 2621 6.8 586 (1.27) 0.22 
*unbound concentration calculated using an internal algorithm that estimates binding from HPLC 
columns coated with HSA and D-glycoprotein. 
Conclusions 
Beginning with an inhaled start point with negligible oral bioavailability, a novel series of selective 
PI3KG inhibitors has been identified with a significantly improved pharmacokinetic profile. Key 
template modifications focused on controlling important physicochemical parameters revealed from 
analysis of data in the target biophase, with particular emphasis on number of aromatic rings, PSA 
and restricting hydrogen bond donors. Through a reduced complexity approach, the 
dihydroisobenzofuran chemotype was identified as a new hinge binding motif and subsequently 
elaborated through the creative application of [2+2+2] cyclo-trimerisation chemistry. This approach 
efficiently and rapidly led to identification of compound 3 which has good oral bioavailability, 
promising PI3K subtype selectivity, as well as highly encouraging levels of efficacy in vivo.  Further 
evolution of this new series of PI3KG inhibitors will be reported in due course, with particular 
emphasis on enhancing the primary activity and selectivity profile, whilst maintaining acceptable 
pharmacokinetic properties. 
Experimental 
Chemistry. General. All solvents and reagents, unless otherwise stated, were commercially available 
from regular suppliers such as Sigma-Aldrich and Fluorochem and were used as purchased without 
further purification. Proton and carbon nuclear magnetic resonance (1H NMR and 13C NMR) spectra 
were recorded on a Bruker AVI (400 MHz), Bruker Nano (400 MHz), or Bruker AVII+ (600 MHz) 
VSHFWURPHWHU ZLWK FU\RSUREH LQ WKH LQGLFDWHG VROYHQW &KHPLFDO VKLIWV į DUH UHSRUWHG LQ SDUWV SHU
million (ppm) relative to tetramethylsilane and are internally referenced to the residual solvent peak. 
Coupling constants (J) are given in Hertz (Hz) to the nearest 0.1 Hz. High resolution mass spectra 
were obtained on a Micromass QTof Ultima hybrid quadrupole time-of-flight mass spectrometer, 
equipped with a Z-spray interface (ESI), over a mass range of 100 í 1100 Da, with a scan time of 0.9s 
and an interscan delay of 0.1 s. Reserpine was used as the external mass calibrant ([M + H]+ = 
609.2812 Da). The Q-Tof Ultima mass spectrometer was operated in W reflectron mode to give a 
UHVROXWLRQIZKPRIí,RQL]DWLRQZDVDFKLHYHGZLWKDVSUD\YROWDJHRIN9DFRQH
YROWDJHRI9ZLWKFRQHDQGGHVROYDWLRQJDVIORZVRIíDQG/KUHVSHFWLYHO\7KHVRXUFH
block and desolvation temperatures were maintained at 120 and 250 °C, respectively. The elemental 
composition was calculated using MassLynx, version 4.1, for the [M + H]+ and the mass error quoted 
as ppm. LCMS methods are detailed in the Supporting Information. The purity of all compounds 
VFUHHQHGLQWKHELRORJLFDODVVD\VZDVH[DPLQHGE\/&06DQDO\VLVDQGZDVIRXQGWREHXQOHVV
otherwise specified. 
N-(5-(1H-indazol-6-yl)-2-methoxypyridin-3-yl)methanesulfonamide (4) 
N-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methanesulfonamide (218 
mg, 0.66 mmol) and 6-bromo-1H-indazole (133 mg, 0.67 mmol) were introduced into a reaction tube 
and 2-Methyltetrahydrofuran (1.5 mL) added. Potassium fluoride (96.0 mg, 1.7 mmol) was dissolved 
in water (0.5 mL) and added into the mixture. The mixture was bubbled through with nitrogen for 4-5 
mins then tri-tert-butylphosphonium tetra-fluoroborate (25 mg, 0.087 mmol) was mixed with 
Tris(dibenzylidene-acetone)dipalladium(0) (30 mg, 0.033 mmol) and added to the mixture. After 1 h, 
further Tri-tert-butyl-phosphonium tetra-fluoroborate (29 mg, 0.100 mmol) was mixed with 
Tris(dibenzylidene-acetone)dipalladium(0) (34 mg, 0.037 mmol) and added to the mixture.The 
resulting mixture was heated at reflux for 19 h before water (10 mL) and of 2-methyltetrahydrofuran 
(10 mL) was added. The organic phase was collected using a hydrophilic cartridge and then loaded 
onto a strong cation exchange (SCX, 20 g) cartridge. This was eluted with of MeOH (30 mL) and then 
of 2N NH3/MeOH (90 mL). The NH3/MeOH fraction was concentrated in vacuo. This sample was 
dissolved in DMSO (3 mL) and purified in 3 x 1 mL runs by mass directed autoprep on Xbridge 
column using acetonitrile/water with a formic acid modifier.  The relevant fractions were combined 
and the solvent was removed under a stream of nitrogen to give 4 (59 mg, 28%). 
LCMS (Method A): 0.74 min, [M+H]+ 319 m/z. 1H NMR (DMSO-d6, 400 MHz) G = 13.16 (s, 1H), 
9.35 (br.s, 1H), 8.35 (d, J = 2.4, 1H), 8.08 (s, 1H), 7.94 (s, J = 2.4, 1H), 7.86 (s, J = 7.6, 1H), 7.71 (s, 
1H), 7.39 (dd, J = 7.6, 1.5, 1H), 3.98 (s, 3H), 3.09 (s, 3H) ppm. 
N-(5-(1,3-dihydroisobenzofuran-5-yl)-2-methoxypyridin-3-yl)methanesulfonamide (5) 
N-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methanesulfonamide 
(0.074 g, 0.23 mmol), 5-bromo-1,3-dihydroisobenzofuran (0.030 g, 0.15 mmol), PdCl2(dppf)-CH2Cl2 
adduct (2.5 mg, 3.00 µmol), cesium carbonate (0.072 g, 0.38 mmol) were combined in 
tetrahydrofuran (1 mL) and water (60 µL). The reaction vessel was sealed and heated in an Anton Parr 
microwave at 100 ºC for 25 min. The solution was then loaded onto C18 SPE (pre-conditioned with 
MeCN/0.1%TFA) and flushed through with a further 3 mLMeCN/0.1%TFA. Solvent was removed 
the residue dissolved in DMSO (0.5 mL) and purified by mass directed autoprep (MDAP) on Sunfire 
C18 column using acetonitrile/water with a formic acid modifier. The solvent was removed under a 
stream of nitrogen to give 5 (20.7 mg, 39%). 
LCMS (Method A): 0.85 min, [M+H]+ 321 m/z. 1H NMR (DMSO-d6, 400 MHz) G = 9.35 (br.s, 1H), 
8.26 (s, 1H), 7.83 (s, 1H), 7.57 (s, 1H), 7.53 (d, J = 7.6,  1H), 7.41 (d, J = 7.6,  1H), 5.09 (s, 2H), 5.05 
(s, 2H), 3.95 (s, 3H), 3.06 (s, 3H) ppm. 
N-(5-(3-hydroxy-3-methylbut-1-yn-1-yl)-2-methoxypyridin-3-yl)methanesulfonamide (19) 
N-(5-bromo-2-methoxypyridin-3-yl)methanesulfonamide (7.03 g, 25 mmol) and copper(I) iodide 
(0.381 g, 2.00 mmol) were dissolved in anhydrous 2-methyltetrahydrofuran (80 mL) and nitrogen was 
bubbled into the mixture during 10 min at room temperature. Then, 2-methylbut-3-yn-2-ol (3.63 mL, 
37.5 mmol), bis(triphenylphosphine)palladium(II) chloride (1.05 g, 1.50 mmol) and triethylamine 
(13.9 mL, 100 mmol) were added and the mixture stirred and heated. After 28 h at 85 ºC, the reaction 
exhibited approximately 60% conversion and 2-methylbut-3-yn-2-ol (1.2mL) and 
bis(triphenylphosphine)palladium(II) chloride (400 mg) added and stirred at 85 ºC for a further 17 h. 
Ammonium chloride (120 mL) and 2-methyltetrahydrofuran (80 mL) were added and the mixture 
filtered through celite. The layers were separated and the aqueous extracted with further 2-
methyltetrahydrofuran (2 x 80 mL). The combined organics were washed with brine, dried over 
sodium sulfate and reduced in vacuo. The resulting residue was purified by column chromatography 
eluting with 0-100% ethyl acetate in cyclohexane. The approppriate fractions were combined and 
reduced in vacuo to provide 19 (7.39 g, 104%, contained residual ethyl acetate). 
LCMS (Method A): 0.73 min, [M+H]+ 285 m/z. 1H NMR (acetone-d6, 400 MHz) G = 8.11 (br.s, 1H), 
7.97 (d, J = 2.4,  1H), 7.73 (d, J = 2.4,  1H), 4.49 (s, 1H), 3.97 (s, 3H), 3.10 (s, 3H), 1.55 (s, 6H) ppm. 
N-[5-ethynyl-2-(methyloxy)-3-pyridinyl]methanesulfonamide (13) 
Potassium hydroxide (9.87 g, 176 mmol) was dissolved in isopropanol (80 mL) at 50ºC over 10 
minutes then 19 (10 g, 35.2 mmol) added in isopropanol (80 mL + 40 mL wash). The mixture was 
heated to reflux (90 ºC) for 4 1/2 hours. Another 0.5 equivalent of potassium hydroxide (0.968 g) was 
added, and the reaction was stirred under reflux (95 ºC) for a further 4 h. The reaction was allowed to 
stand at room temperature for 18 h then reduced in vacuo and partitioned between aqueous 
ammonium chloride (150 mL) and 2-methyl tetrahydrofuran (100 mL). The aqueous layer was 
washed with 2-methyl tetrahydrofuran (2 x 100 mL) and the combined organics washed with brine, 
dried over sodium sulfate and reduced in vacuo. The resulting residue was purified by column 
chromatography eluting with 0-50% ethyl acetate in cyclohexane to give 13 (5.0 g, 60%). 
LCMS (Method A): 0.74 min, [M+H]+ 227 m/z. 1H NMR (acetone-d6, 400 MHz) G = 8.5 (br.s, 1H), 
8.08 (d, J = 2.4,  1H), 7.82 (d, J = 2.4,  1H), 4.01 (s, 3H), 3.74 (s, 1H), 3.12 (s, 3H) ppm. 
N-{2-(Methyloxy)-5-[7-(trimethylsilyl)-1,3-dihydro-2-benzofuran-5-yl]-3-
pyridinyl}methanesulfonamide (14) 
Proceedure A. To a nitrogen degassed solution of 
chloro(pentamethylcyclopentadienyl)(cyclooctadiene)ruthenium(II) (38 mg, 0.1 mmol) and  N-[5-
ethynyl-2-(methyloxy)-3-pyridinyl]methanesulfonamide (226 mg, 1.0 mmol) in CPME (7.5 mL) was 
added a solution of 13 (200 mg, 1.20 mmol) in CPME (7.5 mL) sequentially, dropwise at room 
temperature.  The mixture was then stirred at room temperature for 24 h.  The mixture was 
concentrated under reduced pressure to afford a crude  gum.  The gum was loaded in minimal CH2Cl2 
onto a silica pre-packed column (10 g) and eluted with 0-100% EtOAc in cyclohexane over 60 min.  
The combined relevant fractions were concentrated under reduced pressure to give 14 (250 mg, 64%) 
as a white solid. 
Proceedure B. To chloro(pentamethylcyclopentadienyl)(cyclooctadiene)ruthenium(II) (344 mg, 902 
µmol) was added a solution of 13 (4.1 g, 18 mmol) in CPME (65 mL) and the mixture was degassed 
with three alternative applications of vacuum and nitrogen.  To the mixture was added a solution of 
trimethyl[3-(2-propyn-1-yloxy)-1-propyn-1-yl]silane (1.5 g, 9.0 mmol) in CPME (40 mL) 
sequentially, dropwise at room temperature.  The reaction mixture was then stirred at room 
temperature for 2 h.  The reaction mixture was diluted with ethyl acetate (100 mL) and washed with 
brine (3 x 50 mL). The aqueous extracts were back extracted with ethyl acetate (50 mL). The 
combined organic extracts were dried under reduced pressure to afford a crude gum.   The gum was 
loaded in minimal CH2Cl2 onto a silica pre-packed column (340 g) and eluted with 0-10% EtOAc in 
CH2Cl2 over 12 column volumes.  The combined relevant fractions were concentrated under reduced 
pressure to give 14 (2.26 g, 5.76 mmol, 64 % yield) as a yellow solid.   
m.p. 166 - 167 °C. LCMS (Method A): 1.19 min, [M+H]+ 393 m/z. IR (solid) 3171 (N-H stretch); 
1327, 1137 (O=S=O) cm-1. 1H NMR (DMSO-d6, 400 MHz) G = 9.33 (s, 1H), 8.28 (d, J = 2.3 Hz, 1H), 
7.85 (d, J = 2.3 Hz, 1H), 7.57 (s, 1H), 7.54 (s, 1H), 5.09 (s, 2H), 5.05 (s, 2H), 3.97 (s, 3H), 3.08 (s, 
3H), 0.30 (s, 9H) ppm. 13C NMR (DMSO-d6, 101 MHz): G = 157.2, 144.5, 141.5, 140.3, 136.4, 134.2, 
          SSP +506 (6, FDOF¶G IRU
C18H25N2O4SSi [M+H]+  393.1299, found 393.1298. 
N-[5-(7-Iodo-1,3-dihydro-2-benzofuran-5-yl)-2-(methyloxy)-3-pyridinyl]methanesulfonamide 
(15) 
Iodine monochloride in CH2Cl2 (1 M, 4.33 mL, 4.33 mmol) was added dropwise to a solution of 14 
(850 mg, 2.17 mmol) in CH2Cl2 (20 mL) under nitrogen at -10 ºC. The reaction mixture was allowed 
to warm to 0 ºC and stirred for 5 minutes, during which a white solid precipitated from solution.  
Saturated sodium thiosulfate solution (50 mL) was added and the resulting mixture stirred at room 
temperature for 20 min.  The reaction mixture was filtered under reduced pressure and washed with 
CH2Cl2 (5 mL).  The filtrate was poured onto CH2Cl2 (50 mL) and water (30 mL) and the separated 
aqueous phase was extracted with CH2Cl2 (2 x 50 mL).  The combined organic fractions were passed 
through a hydrophobic frit then concentrated under vacuum to afford a yellow solid.  The yellow solid 
and white solid were combined and triturated in methanol (5 mL).  The mixture was filtered under 
reduced pressure and the solid was dried in a vacuum oven for 2 h to afford 15 (774 mg, 1.73 mmol, 
80%) as a white solid. LCMS (Method A): 1.06 min, [M+H]+ 447 m/z.  1H NMR (DMSO-d6, 400 
MHz): G = 9.26 - 9.39 (m, 1H), 8.28 (d, J = 2.3 Hz, 1H), 7.89 (s, 1H), 7.85 (d, J = 2.3 Hz, 1H), 7.59 
(s, 1H), 5.21 (s, 2H), 4.92 (s, 2H), 3.96 (s, 3H), 3.09 (s, 3H) ppm. 13C NMR (101 MHz, DMSO-d6): G 
= 156.8, 143.2, 141.5, 141.1, 138.8, 134.3, 131.0, 128.8, 121.9, 119.8, 89.0, 76.9, 74.7, 54.3, 41.2 
ppm. 
N-(5-(7-Amino-1,3-dihydroisobenzofuran-5-yl)-2-methoxypyridin-3-yl)methanesulfonamide (16) 
L-proline (413 mg, 3.59 mmol), copper(I) iodide (68 mg, 0.36 mmol), cesium carbonate (1.75 g, 5.38 
mmol) and 15 (800 mg, 1.79 mmol) were evenly charged over 2 microwave vials (2 x 20 mL).  The 
vials was sealed and degassed before aqueous ammonia solution 0.88 (35%, 8.0 mL, 0.13 mol) and 
DMSO (8 mL) were added via syringe and the vials were heated and stirred in a Biotage microwave 
reactor at 50 ºC for 2 h.  After this time aqueous ammonia solution 0.88 (35%, 2 x 4 mL, 0.2 mol) and 
cesium carbonate (2 x 500 mg, 1.53 mmol) was added via syringe to both vials and the vials were 
heated and stirred at 110 ºC for 6 h.  The reaction mixtures were combined and filtered under reduced 
pressure, then washed with methanol.  The filtrate was loaded directly onto a SCX cartridge (70 g) 
and flushed with methanol (200 mL) under reduced pressure.  The column was then eluted with 
ammonia in methanol solution (7 M, 300 mL) under reduced pressure.  The filtrate was concentrated 
under reduced pressure to afford a crude gum.  The gum was dissolved in CH2Cl2 (30 mL) and 
washed three times with water.  The combined organic fractions were filtered through a hydrophobic 
frit and concentrated under reduced pressure to afford 16 (460 mg, 1.37 mmol, 77%) as a white solid. 
m.p. 295 - 301 °C. LCMS (Method A): 0.65 min, [M+H]+ 336 m/z. IR (solid) 3467, 3377 (H-N-H 
stretch); 3049 (N-H stretch); 1303, 1138 (O=S=O) cm-1. 1H NMR (DMSO-d6, 400 MHz): G = 9.28 
(br. s., 1H), 8.17 (d, J = 2.3 Hz, 1H), 7.77 (d, J = 2.3 Hz, 1H), 6.64 - 6.78 (m, 2H), 5.25 (s, 2H), 4.97 
(s, 2H), 4.88 (s, 2H), 3.96 (s, 3H), 3.07 (s, 3H) ppm. 13C NMR (DMSO-d6, 101 MHz): G = 155.8, 
142.9, 140.8, 140.0, 137.1, 130.6, 130.5, 122.3, 121.1, 110.7, 106.6, 73.2, 71.5, 53.7, 40.6 ppm.  
+506(6,FDOF¶GIRU&15H18N3O4S [M+H]+ 336.1013, found 336.1017. 
 
N-(2-Methoxy-5-(7-(5-methyl-1,3,4-oxadiazol-2-yl)-1,3-dihydroisobenzofuran-5-yl)pyridin-3-
yl)methanesulfonamide (6) 
A microwave vial was charged with 2-methyl-1,3,4-oxadiazole (45 mg, 0.54 mmol) and THF (1.5 
mL).  Zinc chloride (244 mg, 1.79 mmol) was added and the mixture was degassed and cooled to -10 
ºC under nitrogen.  A solution RIOLWKLXPKH[DPHWK\OGLVLOD]LGHLQ7+)0ȝ/ȝPROZDV
then added dropwise over 15 min at -10 °C.  The resulting mixture was stirred at    -10 °C (+/-5 °C) 
for 1 h.  15 (200 mg, 450 µmol), tetrakis(triphenylphosphine)palladium(0) (52 mg, 45 ȝPRO DQG
cesium carbonate (146 mg, 448 µmol) were then added at -10 °C.   The mixture was then degassed  
with three alternative applications of vacuum and nitrogen, then heated in a Biotage microwave at 150 
ºC for 1 h.    The mixture was poured onto CH2Cl2 (20 mL) and the mixture was filtered under 
reduced pressure.  The filtrate was extracted with CH2Cl2 (3 x 50 mL) and the combined organic 
phase was treated with water (50 mL).  The resulting mixture was filtered under reduced pressure and 
washed with CH2Cl2 (3 x 50 mL).  The filtrate was passed through a hydrophobic frit and then 
concentrated under reduced pressure to afford a yellow solid.  The solid was loaded in DMSO (1 mL) 
and purified via mass directed auto-preparative (MDAP) chromatography using a Sunfire C18 column 
and an ammonium bicarbonate-modified MeCN/water gradient.  The relevant combined fractions 
were concentrated under reduced pressure to give 6 (45 mg, 0.11 mmol, 24%) as a white solid. LCMS 
(Method A): 0.78 min, [M+H]+ 403. IR (solid) 2929 (N-H stretch); 1331, 1149 (O=S=O) cm-1. 1H 
NMR (DMSO-d6, 400 MHz): G = 9.37 (s, 1H), 8.37 (d, J = 2.3 Hz, 1 H), 8.02 (d, J = 1.3 Hz, 1H), 
7.94 (d, J = 2.3 Hz, 1H), 7.84 (s, 1H), 5.34 (s, 2H), 5.17 (s, 2H), 3.99 (s, 3H), 3.10 (s, 3H), 2.62 (s, 
3H) ppm. 13C NMR (101 MHz, DMSO-d6) G = 164.4, 163.3, 156.9, 142.7, 140.6, 137.8, 137.7, 130.6, 
          SSP  +506 (6, FDOF¶G IRU
C18H19N4O5S [M+H]+ 403.1071, found 403.1070. 
N-(2-Methoxy-5-(7-(pyridin-2-yl)-1,3-dihydroisobenzofuran-5-yl)pyridin-3-
yl)methanesulfonamide (7) 
A microwave vial was charged with 15 (70 mg, 0.16 mmol), 2-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)pyridine (80 mg, 0.39 mmol), cesium carbonate (102 mg, 0.310 mmol), copper(I) 
chloride (16 mg, 0.16 mmol), palladium(II) acetate (0.5 mg, 2 µmol), 1,1'-
bis(diphenylphosphino)ferrocene (dppf) (18 mg, 30 ȝmol) and DMF (1.5 mL).  The vial was sealed 
and degassed then heated and stirred in a Biotage microwave reactor at 100 ºC for 90 min.  The 
mixture was poured onto water (20 mL) and EtOAc (20 mL) and the mixture was then filtered under 
reduced pressure.  The separated aqueous phase was extracted with EtOAc (3 x 20 mL) and the 
combined organic phase was filtered. The filtrate was concentrated under reduced pressure to afford a 
brown solid.  The solid was loaded in DMSO/MeOH solution (1:1 (v/v) 1 mL) and purified via mass 
directed auto-preparative (MDAP) chromatography using a Sunfire C18 column and an ammonium 
bicarbonate-modified MeCN/water gradient.  The relevant combined fractions were concentrated 
under reduced pressure to give 7 (6 mg, 0.02 mmol, 10%) as a white solid. LCMS (Method A): 0.89 
min, [M+H]+ 398 m/z. 1H NMR (DMSO-d6, 400 MHz,) G = 9.07-9.43 (m, 1H), 8.70 (d, J = 4.03 Hz, 
1H), 8.41 (d, J = 2.01 Hz, 1H), 8.06 (s, 2H), 7.90-8.00 (m, 2H), 7.65 (s, 1H), 7.39 (dd, J = 5.16, 6.92 
Hz, 1H), 5.38 (s, 2H), 5.11 (s, 2H), 3.99 (s, 3H), 3.09 (s, 3H) ppm. 
N-(6-(6-Methoxy-5-(methylsulfonamido)pyridin-3-yl)-1,3-dihydroisobenzofuran-4-yl)acetamide 
(8) 
Acetic acid (10 µL, 0.15 mmol) was added dropwise to a stirred suspension of HATU (62 mg, 0.16 
PPRO DQG ',3($  ȝ/  PPRO LQ &+2Cl2 (1 mL) at room temperature.  The mixture was 
stirred for 10 min at room temperature, during which time the milky suspension turned into a yellow 
solution.  A suspension of 16 (50 mg, 0.15 mmol) in CH2Cl2 (1 mL) was then added dropwise to the 
mixture at room temperature.  DMF (10 µL) was added and the solution was stirred for 16 h at room 
temperature.  The solution was poured onto EtOAc (2 mL) and brine (3 mL) and the separated organic 
phase was washed with brine (2 x 3 mL).  The combined organic phase was concentrated under a 
stream of nitrogen to give an orange gum.  The gum was dissolved in DMSO/MeOH (1 mL, 1:1 v/v) 
and purified via mass directed auto-preparative (MDAP) chromatography using a Sunfire C18 column 
and an ammonium bicarbonate-modified MeCN/water gradient.  The relevant combined fractions 
were concentrated under reduced pressure to give a white solid.  Water (10 mL) and diethyl ether (10 
mL) was added and the mixture filtered and the filter cake was dried under reduced pressure to give 8 
PJȝPRODVDZKLWHVROLGPS - 228 °C. LCMS (Method A): 0.67 min, [M+H]+ 
378 m/z. IR (solid) 3240 (N-H stretch); 3080 (N-H stretch); 1629 (C=O); 1321, 1144 (O=S=O) cm-
1.1H NMR (DMSO-d6, 400 MHz): į = 9.77 (s, 1H), 9.37 (s, 1H), 8.23 (s, 1H), 7.81 (s, 1H), 7.65 (s, 
1H), 7.34 (s, 1H), 5.05 (s, 2H), 4.96 (s, 2H), 3.96 (s, 3H), 3.07 (s, 3H), 2.07 (s, 3H) ppm. 13C NMR 
(101 MHz, DMSO-d6į 
      SSP  +506 (6, FDOF¶G IRU &17H20N3O5S [M+H]+ 378.1118, 
found 378.1120. 
N-(6-(6-Methoxy-5-(methylsulfonamido)pyridin-3-yl)-1,3-dihydroisobenzofuran-4-yl)-2-
methylthiazole-4-carboxamide (9) 
',3($  ȝ/  PPRO DQG +$78  PJ  PPRO ZHUH DGGHG VHTXHQWLDOO\ WR D VWLUUHG
solution of 2-methyl-1,3-thiazole-4-FDUER[\OLF DFLG  PJ  ȝPRO LQ '0)  P/ DW URRP
temperature and the solution stirred for 10 min.   A solution of 16 (50 mg, 0.15 mmol) in DMF (0.5 
mL) was then added dropwise at room temperature and the solution stirred at room temperature for 16 
h, during which time a white solid precipitated. The mixture was filtered under reduced pressure and 
washed with water (10 mL) then diethyl ether (10 mL).  The white solid was dried in a vacuum oven 
for 16 h to afford 9 PJȝPRO, 21%) as a white solid. m.p. 274 - 277 °C. LCMS (Method 
A): 0.89 min, [M+H]+ 461 m/z. IR (solid) 3379 (N-H stretch); 3141 (N-H stretch); 1671 (C=O); 1324, 
1136 (O=S=O) cm-1.  1H NMR (DMSO-d6, 400 MHz): G = 10.30 (s, 1H), 9.39 (s, 1H), 8.25 - 8.44 (m, 
2H), 7.93 (d, J = 2.3 Hz, 1H), 7.71 (s, 1H), 7.49 (s, 1H), 5.15 (s, 2H), 5.07 (s, 2H), 4.03 (s, 3H), 3.14 
(s, 3H), 2.83 (s, 3H) ppm. 13C NMR (DMSO-d6, 101 MHz): G = 166.2, 158.8, 156.0, 148.7, 142.1, 
140.1, 136.9, 132.6, 132.1, 130.6, 129.3, 125.4, 121.5, 120.8, 115.8, 72.7, 72.2, 53.7, 40.7, 18.8 ppm. 
+506(6,FDOF¶GIRU&20H21N4O5S2 [M+H]+ 461.0948, found 461.0951. 
N-(6-(6-Methoxy-5-(methylsulfonamido)pyridin-3-yl)-1,3-dihydroisobenzofuran-4-yl)-2-
morpholinoacetamide (3) 
',3($  ȝ/  PPRO DQG +$78  PJ  PRO ZHUH DGGHG VHTXHQWLDOO\ WR D VWLUUHG
solution of morpholin-4-yl-acetic acid (35 mg, 0.24 mmol) in DMF (0.5 mL) at room temperature.  
The reaction was stirred for 10 min at room temperature. A solution of 16 (80 mg, 0.24 mmol) in 
DMF (0.5 mL) was then added dropwise to the reaction mixture at room temperature and the mixture 
was stirred at room temperature for 16 h. The mixture was poured onto EtOAc (2 mL) and brine (3 
mL) and the separated organic phase was washed with brine (2 x 3 mL).  The combined organic phase 
was concentrated under a stream of nitrogen to give an orange gum.  The gum was dissolved in 
DMSO/MeOH (1 mL, 1:1 v/v) and purified via mass directed auto-preparative (MDAP) 
chromatography using a Sunfire C18 column and an ammonium bicarbonate-modified MeCN/water 
gradient.  The relevant fractions were combined and the volume reduced by 70% under a stream of 
nitrogen.  A white solid precipitated from solution.  The mixture was filtered under reduced pressure 
and washed with water (10 mL) then diethyl ether (10 mL) and then dried in a vacuum oven for 1 
hour to afford 3 PJȝPRODVDZKLWHVROLGPS- 220 °C. LCMS (Method A): 0.54 
min, [M+H]+ 463 m/z.  IR (solid) 3224 (N-H stretch); 2925 (N-H stretch); 2852 (C-H stretch); 1658 
(C=O); 1318, 1142 (O=S=O) cm-1.  1H NMR (DMSO-d6, 400 MHz): G = 9.63 (s, 1H), 9.24 - 9.46 (m, 
1H), 8.24 (d, J = 2.3 Hz, 1H), 7.83 (d, J = 2.3 Hz, 1H), 7.67 (s, 1H), 7.37 (s, 1H), 5.07 (s, 2H), 4.98 (s, 
2H), 3.96 (s, 3H), 3.65 (t, J = 4.5 Hz, 4H), 3.15 (s, 2H), 3.07 (s, 3H), 2.53 (t, J = 4.5 Hz, 4H) ppm. 13C 
NMR (DMSO-d6, 101 MHz): G = 168.0, 156.1, 141.6, 140.3, 136.6, 133.1, 130.7, 130.4, 129.6, 121.3, 
118.8, 115.0, 72.8, 72.1, 53.8, 40.7, 40.2, 38.9, 23.4 ppm.  H506 (6, FDOF¶G IRU &21H27N4O6S 
[M+H]+ 463.1651, found 463.1656. 
N-(6-(6-Methoxy-5-(methylsulfonamido)pyridin-3-yl)-1,3-dihydroisobenzofuran-4-yl)-6-
methylpicolinamide (10) 
',3($  ȝ/  PPRO DQG +$78  PJ  PPRO ZHUH DGGHG VHTXHQWLDOO\ WR D VWLUUHG
solution of 6-methylpicolinic acid (33 mg, 0.24 mmol) in DMF (0.5 mL) at room temperature and the 
solution stirred for 10 min.  A solution of 16  (50 mg, 0.15 mmol) in DMF (0.5 mL) was then added 
dropwise at room temperature and the mixture stirred at room temperature overnight. The reaction 
mixture was poured onto EtOAc (2 mL) and brine (3 mL) and the separated organic phase was 
washed with brine (2 x 3 mL).  The combined organic phase was concentrated under a stream of 
nitrogen to give an orange gum.  The gum was loaded in a solution of DMSO/MeOH (1 mL, 1:1 v/v) 
and purified via mass directed auto-preparative (MDAP) chromatography using a Sunfire C18 column 
and an ammonium bicarbonate-modified MeCN/water gradient.  The relevant fractions were 
combined and concentrated under a stream of nitrogen to give 10 PJȝPRODVDZKLWH
solid. LCMS (Method A): 0.99 min, [M+H]+ 455 m/z. 1H NMR (DMSO-d6, 400 MHz): G = 10.49 (s, 
1H), 9.26 - 9.57 (br. s, 1H), 8.31 (d, J = 2.3 Hz, 1H), 7.94 - 7.99 (m, 2H), 7.89 (d, J =2.3 Hz, 1H), 
7.81 (s, 1H), 7.56 (dd, J = 6.2, 2.4 Hz, 1H), 7.46 (s, 1H), 5.11 (s, 2H), 5.07 (s, 2H), 3.98 (s, 3H), 3.09 
(s, 3H), 2.64 (s, 3H) ppm. 
Biology. 3,.Į -ȕ -Ȗ DQG -į +75) $VVD\V Inhibition of PI3 Kinase enzymatic activity was 
determined using a homogeneous time-resolved fluorescence (HTRF) kit assay format provided by 
Millipore. Reactions were performed in assay buffer containing 50 mM HEPES, pH 7.0, 150 mM 
NaCl, 10 mM MgCl2, <1% cholate (w/v), <1% CHAPS (w/v), 0.05% sodium azide (w/v), and 1 mM 
DTT. Enzymes were preincubated with compound, serially diluted 4-fold in 100% DMSO, for 15 min 
prior to reaction initiation upon addition of substrate solution containing ATP at Km for the specific 
LVRIRUPWHVWHGĮDWȝ0ȕDWȝ0įDWȝ0DQGȖDWȝ03,3DWHLWKHUȝ03,.į
RUȝ03,.Į-ȕDQG-ȖDQGQ0ELRWLQ-PIP3. Assays were quenched after 60 min by addition 
of a quench/detection solution prepared in 50 mM HEPES, pH 7.0, 150 mM NaCl, <1% cholate, <1% 
Tween 20, 30 mM EDTA, 40 mM potassium fluoride, and 1 mM DTT containing 16.5 nM GRP- 1 
PH domain, 8.3 nM streptavidin-APC, and 2 nM europium-antiGST and were left for a further 60 min 
in the dark to equilibrate prior to reading using a BMG RubyStar plate reader. Ratio data were 
normalized to high (no compound) and low (no enzyme) controls prior to fitting using a logistical 
four-parameter equation to determine IC50. 
Peripheral Blood Mononuclear (PBMC) Assay. Reagents were purchased from Invitrogen 
Corporation Ltd. unless otherwise specified. PBMC cells (peripheral blood mononuclear cells) were 
prepared from heparinized human blood (using 1% v/v heparin sodium 1000 U/mL endotoxin free, 
Leo Laboratories Ltd.) using the Accuspin system-Histopaque-1077 (Sigma-Aldrich Company Ltd.). 
The cells were resuspended in RPMI1640 medium containing 10% fetal calf serum, 1% L-glutamine, 
and 1% penicillin/streptomycin. The cells at a density of 5 × 105 viable cells/mL were incubated with 
0.0156% (v/v) CytoStim (Miltenyi Biotech). The assay plate was then incubated at 37 °C, 5% CO2, 
IRU  K 7KH VXSHUQDWDQW ZDV UHPRYHG DQG WKH FRQFHQWUDWLRQV RI ,)1Ȗ ZHUH GHWHUPLQHG E\
electrochemiluminescence assay using the Meso Scale Discovery (MSD) technology (Meso Scale 
Discovery). 
Brown Norway Rat Acute OVA Model of Th2 Driven Lung Inflammation. All reagents unless 
stated were from Sigma-Aldrich. The models used in these studies conform to U.K. standards of 
animal care, as laid down by the Home Office. Procedures were carried out as exactly specified under 
*OD[R6PLWK.OLQH¶V 5HVSLUDWRU\ 'LVHDVHV 3URMHFW OLFHQVH 33/  DQG  0DOH EURZQ
1RUZD\%1UDWVZHLJKLQJíJZHUHVHQVLWL]HGE\LQWUDSHUitoneal injection of a 1 mL OVA 
VROXWLRQFRQWDLQLQJȝJRI29$DQGPJRI$O2+3 on days 1 and 7. On day 21 or 28, rats were 
challenged with 0.2 mL of intratracheal OVA solution under isoflurane (Abbott Laboratories) 
anesthesia. Compound in vehicle (0.2% Tween 80, water, pH 4.5) or vehicle alone was also dosed by 
i.t. route (0.2 mL volume) at t íPLQDQGKUHODWLYHWRLQWUDWUDFKHDO29$FKDOOHQJHKDIWHU
i.t. OVA challenge rats were sacrificed by anesthetic overdose. The trachea was exposed and lungs 
were lavaged with 5 mL of lavage fluid (0.1% BSA, 10 mM EDTA, and 1 protease inhibitor tablet, 
catalog no. 11873580001 from Roche, per 50 mL). Death was confirmed by cervical dislocation. BAL 
was immediately transferred onto ice, and leucocytes were then quantified by flow cytometry. Briefly, 
samples were read on a BD FACSCANTO II 8 color flow cytometer. Lymphocytes, eosinophils, 
neutrophils, and macrophages were gated on FSC and SSC using morphological criteria. Threshold 
was set on FSC channel. In some studies the Amcyan channel was used to gate cells further using 
autofluorescence (intersecting gates). DAPI+ cells were excluded as dead. For cytokine analysis mice 
were lavaged 24 h after OVA challenge. BAL was spun at 4 °C at 300g for 7 min and the supernatant 
stored at 20 °C prior to analysis. Data from repeat studies were average-standardized, pooled, and a 
four-parameter nonlinear logistic curve was fitted. 
Pharmacokinetic Studies. In vitro clearance was determined to assess metabolic stability of 
FRPSRXQGVLQUDWPLFURVRPHV0LFURVRPHVȝ/PJRISURWHLQP/ZHUHSUHZDUPHGIRU 
PLQDW&7KHLQFXEDWLRQZDVLQLWLDWHGE\DGGLWLRQRI1$'3+UHJHQHUDWLRQV\VWHPȝ/DQG
FRPSRXQGȝ/ȝ0UHVXOWLQJLQDILQDOFRPSRXQGFRQFHQWUDWLRQRIȝ0LQWKHLQFXEDWLRQ
6DPSOHVȝ/ZHUHUHPRYHGDWDQGPLQDQd the reaction was quenched by addition 
WRDFHWRQLWULOHȝ/FRQWDLQLQJLQWHUQDOVWDQGDUG,6&RPSRXQGUHPDLQLQJZDVPHDVXUHGXVLQJ
VSHFLILF/&í0606PHWKRGVDVDUDWLRWRWKHLQWHUQDOVWDQGDUGLQWKHDEVHQFHRIDFDOLEUDWLRQFXUYH
Peak area ratios (compound to IS) were fitted to an unweighted logarithmic decline in substrate. By 
use of the first order rate constant, clearance was calculated by adjustment for protein concentration 
PJP/YROXPHRIWKHLQFXEDWLRQȝ/DQGKHSDWLFVFDOLQJIDctor (52.5 mg of microsomal 
protein/g of liver). HSA binding was measured via chormatographic analysis according to the 
published methodology.32 Passive membrane permeability was determined in MDCKII-MDR1 cells, 
at pH 7.4 in the presence of a potent P-glycoprotein inhibitor.  Each compounds was incubated in 
duplicate at a concentration of 3 mM on one test occasion.  In this assay the passive apparent 
permeability (Papp) is reported in nm/sec (single test occasion). In vivo pharmacokinetics was tested in 
Sprague Dawley male rats. Compounds were administered discretely by the oral and intravenous 
routes at dose levels of 3 and 1 mg/kg, respectively (n = 2 rats/route). Compounds were formulated as 
a solution in DMSO/PEG200/water (5:45:50 v/v/v) at a dose volume of 6 (oral) and 2 (intravenous) 
mL/ kg. All animals were serially bled from the tail vein, and blood samples collected over a time-
FRXUVH RI í K ZHUH VXEPLWWHG WR /&í0606 DQDO\VLV IRU WKH TXDQWLILFDWLRQ RI WKH SDUHQW
compound. The main pharmacokinetic parameters were estimated by noncompartmental analysis. 
Chemiluminescent Nitrogen Detection (CLND) Solubility Determination. GSK in-house kinetic 
VROXELOLW\DVVD\LQYROYHGWKHIROORZLQJP/RIP0'062VWRFNVROXWLRQGLOXWHGWRȝ/ZLWK
pH 7.4 phosphate buffered saline, equilibrated for 1 h at room temperature, filtered through Millipore 
Multiscreen HTS-PCF filter plates (MSSL BPC). The filtrate was quantified by suitably calibrated 
flow injection chemiluminescent nitrogen detection.33 The standard error of the CLND solubility 
GHWHUPLQDWLRQZDVȝ0DQG WKHXSSHU OLPLWRI WKHVROXELOLW\ LVȝ0ZKHQZRUNLQJIURP
mM DMSO stock solution.  
All animal studies were ethically reviewed and carried out in accordance with Animals (Scientific 
Procedures) Act 1986 and the GSK Policy on the Care, Welfare and Treatment of Laboratory 
Animals. The human biological samples were sourced ethically, and their research use was in accord 
with the terms of the informed consents. 
Footnotes: 
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